The company claims it achieves superior resolution in signal and time compared to traditional Surface Plasmon Resonance (SPR)
Domainex has invested in the WAVEdelta instrument from Creoptix. The instrument employs grating-coupled interferometry (GCI) to measure target binding on sensor chips, generating binding affinity and on/off rate kinetics in a high throughput manner.
Under the terms of the agreement, Creoptix has delivered its latest pre-launch WAVEdelta system with its waveRAPID (repeated analyte pulses of increasing duration) capability built in, to be officially launched in February 2021. This is aimed to increase throughput dramatically and reduce compound consumption with timed pulsed injections. Domainex has also been appointed to a partnering program under which Creoptix will refer “fee-for-service” enquiries to Domainex.
Dr Tom Mander, CEO at Domainex, said: “I have been impressed with the technical expertise and access the team at Creoptix have given us, under Line’s stewardship. We are pleased to have become one of only three companies to join their partnering program. The WAVEdelta system will complement our already comprehensive and world-leading biophysical screening platform. Alongside this, we have recruited more talented scientists with prior experience to cater to the growing demand for such services”.
Line Stigen Raquet, CEO of Creoptix, added: “We are very pleased to embark on our partnership with Domainex and grant them early access to our waveRAPID technology as part of our Partnering Program. Domainex and Creoptix share a strong commitment to our customers and helping them achieve scientific breakthroughs, and we are delighted to join forces in the pursuit of this goal”.